Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Kimia Farma Persero TbkISX:KAEF +0.46%55 Piotroski F-Score is 7 as of Aug. 17, 2026, which is 40% above its 10-year median of 5.00. GuruFocus rates ISX:KAEF with a GF Score™ of 55/100 and a GF Value™ of Rp579.86 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 113 Medical Distribution companies, PT Kimia Farma Persero Tbk ranks better than 88.5% on this metric.
Good Sign:
Piotroski F-Score is 7, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
PT Kimia Farma Persero Tbk has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
The historical rank and industry rank for PT Kimia Farma Persero Tbk's Piotroski F-Score or its related term are showing as below:
ISX:KAEF'
s Piotroski F-Score Range Over the Past 10 Years
Min: 2 Med: 5 Max: 7
Current: 7
During the past 13 years, the highest Piotroski F-Score of PT Kimia Farma Persero Tbk was 7. The lowest was 2. And the median was 5.
PT Kimia Farma Persero Tbk (ISX:KAEF) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
PT Kimia Farma Persero Tbk Piotroski F-Score Related Terms
PT Kimia Farma Persero Tbk Piotroski F-Score Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Kimia Farma Persero Tbk Piotroski F-Score Chart
ISX:KAEF vs MCK, COR, CAH: Piotroski F-Score Comparison
For the Medical Distribution subindustry, PT Kimia Farma Persero Tbk's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Kimia Farma Persero Tbk Piotroski F-Score vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, PT Kimia Farma Persero Tbk's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where PT Kimia Farma Persero Tbk's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
This Year (Jun26) TTM:
Last Year (Jun25) TTM:
Net Income was -84716.853 + -155227.354 + 74449.544 + -64123.674 = Rp-229,618 Mil. Cash Flow from Operations was 190619.856 + 118549.345 + 87100.568 + -180204.471 = Rp216,065 Mil. Revenue was 2638862.719 + 2215116.743 + 2030649.486 + 2671041.11 = Rp9,555,670 Mil. Gross Profit was 883784.799 + 618330.791 + 824816.869 + 847209.871 = Rp3,174,142 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(14973271.31 + 14910941.488 + 14183178.39 + 14358871.134 + 14698071.465) / 5 = Rp14624866.7574 Mil. Total Assets at the begining of this year (Jun25) was Rp14,973,271 Mil. Long-Term Debt & Capital Lease Obligation was Rp6,410,417 Mil. Total Current Assets was Rp4,767,564 Mil. Total Current Liabilities was Rp4,610,372 Mil.
Net Income was -195052.487 + -420438.304 + -102177.254 + 7162.125 = Rp-710,506 Mil.
Revenue was 2650568.513 + 2074694.366 + 2168207.817 + 2201140.777 = Rp9,094,611 Mil. Gross Profit was 773933.181 + 592857.115 + 742671.671 + 818623.117 = Rp2,928,085 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(17067208.218 + 16802347.355 + 14928543.991 + 15026459.88 + 14973271.31) / 5 = Rp15759566.1508 Mil. Total Assets at the begining of last year (Jun24) was Rp17,067,208 Mil. Long-Term Debt & Capital Lease Obligation was Rp3,910,198 Mil. Total Current Assets was Rp4,092,448 Mil. Total Current Liabilities was Rp6,894,591 Mil.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
PT Kimia Farma Persero Tbk's current Net Income (TTM) was -229,618.
==> Negative ==> Score 0.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
PT Kimia Farma Persero Tbk's current Cash Flow from Operations (TTM) was 216,065.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
PT Kimia Farma Persero Tbk's return on assets of this year was -0.01533522. PT Kimia Farma Persero Tbk's return on assets of last year was -0.04162989.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
PT Kimia Farma Persero Tbk's gearing of this year was 0.43832309. PT Kimia Farma Persero Tbk's gearing of last year was 0.24811587.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
PT Kimia Farma Persero Tbk's current ratio of this year was 1.03409528. PT Kimia Farma Persero Tbk's current ratio of last year was 0.59357372.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
PT Kimia Farma Persero Tbk's number of shares in issue this year was 5566.588. PT Kimia Farma Persero Tbk's number of shares in issue last year was 5566.588.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
PT Kimia Farma Persero Tbk's gross margin of this year was 0.33217371. PT Kimia Farma Persero Tbk's gross margin of last year was 0.32195824.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
PT Kimia Farma Persero Tbk's asset turnover of this year was 0.63818185. PT Kimia Farma Persero Tbk's asset turnover of last year was 0.53287048.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
0
+
1
+
1
+
1
+
0
+
1
+
1
+
1
+
1
=
7
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
PT Kimia Farma Persero Tbk has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
PT Kimia Farma Persero Tbk (ISX:KAEF) has a Piotroski F-Score of 7 as of Aug. 17, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on PT Kimia Farma Persero Tbk and its competitors. This is 40% above median its historical median of 5.00. Over the past decade, PT Kimia Farma Persero Tbk's Piotroski F-Score has ranged from 2.00 to 7.00. According to the industry distribution chart, PT Kimia Farma Persero Tbk ranks #13 out of 113 companies in the Medical Distribution industry, placing it in the top 11.5%.
Is PT Kimia Farma Persero Tbk's Piotroski F-Score too high?
PT Kimia Farma Persero Tbk's current Piotroski F-Score of 7 is 40% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 7.00. The Medical Distribution industry median Piotroski F-Score is 5.00. PT Kimia Farma Persero Tbk's value of 7 is 40% above this industry median. Based on the distribution chart, PT Kimia Farma Persero Tbk ranks #13 out of 113 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, PT Kimia Farma Persero Tbk has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Kimia Farma Persero Tbk's Piotroski F-Score compare to MCK and COR?
According to the Medical Distribution industry distribution chart, PT Kimia Farma Persero Tbk ranks #13 out of 113 companies for Piotroski F-Score. This places PT Kimia Farma Persero Tbk in the top 12% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. PT Kimia Farma Persero Tbk's value of 7 is 40% above this benchmark. Historically, PT Kimia Farma Persero Tbk's own Piotroski F-Score has ranged from 2.00 to 7.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, PT Kimia Farma Persero Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Distribution company?
The median Piotroski F-Score among Medical Distribution companies is 5.00, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Kimia Farma Persero Tbk's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on PT Kimia Farma Persero Tbk and its competitors. For the Medical Distribution industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Kimia Farma Persero Tbk's current Piotroski F-Score is 7, which is 40% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Kimia Farma Persero Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Kimia Farma Persero Tbk (ISX:KAEF) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp579.86, compared to a current price of Rp440.00 — trading 24.1% below its estimated fair value. The current Piotroski F-Score is 7, which is 40% above median its 10-year median of 5.00 and 40% above the Medical Distribution industry median of 5.00. PT Kimia Farma Persero Tbk's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For PT Kimia Farma Persero Tbk (ISX:KAEF), the current Piotroski F-Score is 7 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Kimia Farma Persero Tbk (ISX:KAEF) Overvalued in 2026?
Based on GuruFocus' analysis, PT Kimia Farma Persero Tbk stock appears to be undervalued.
The current stock price of Rp440.00 is trading 24.1% below its estimated GF Value™ of Rp579.86.
GuruFocus considers PT Kimia Farma Persero Tbk to be Modestly Undervalued.
Key valuation signals for ISX:KAEF:
Piotroski F-Score: 7 (40% above median its 10-year median of 5.00)
GF Value™: Rp579.86 vs. price of Rp440.00 (24.1% below fair value)
Industry Position: 40% above the Medical Distribution median (#13 of 113)
No single metric tells the full story. See the ISX:KAEF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Kimia Farma Tbk is an Indonesia-based company engaged in the production and distribution of healthcare products. It operates through the following segments: Manufacture, Distribution, Retail, and Others. The company provides its products in categories including OTC & Herb, Ethical, Cosmetic, Generic, and others. Some of its product offerings include Alergine, Kimoxil, Loprezol, Enkasari, and Batugin among others. It generates maximum revenue from the Retail segment.
55GF Score
Get the complete analysis for ISX:KAEF
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:KAEF has been successfully added to your 
